Beta Bionics, known for its iLet insulin pump, continues its development of a bi-hormonal pump—a closed-loop system that delivers both insulin and glucagon to more closely mimic a healthy pancreas. This dual-hormone approach not only helps tighten blood sugar differentiation but can also prevents hypoglycemia, offering a safer and responsive management option for people with diabetes.

The company teamed up with Xeris Pharmaceuticals to tackle one of the biggest hurdles: a stable, pump-compatible glucagon formulation. Since glucagon traditionally degrades quickly, this collaboration is key to making bi-hormonal delivery reliable.

The potential benefits of an dual insulin-glucagon pump are huge:

While there’s no public launch date yet, Beta Bionics confirms that a bi-hormonal pump remains a top priority—backed by investor support and ongoing clinical efforts.

I sat down with Beta Bionics founder and iLet inventor Ed Damiano to explore how the bi-hormonal pump works, its future potential, and what’s still to come. We also talk about the journey of developing this device, why glucagon was such a challenge, and how the company is aiming for more freedom and safety in diabetes care. Watch the full interview above or listen to the full episode on your favorite podcast platform.

Bonus sneak peek: Beta Bionics is also working on a new tubeless insulin pump called Mint—and I got to see it in person at ADA 2025 in Chicago. This exciting new device could be a game-changer for those looking for a more discreet, wearable option. Stay tuned for more on this innovation!

For the latest diabetes tech, join our newsletter. And if you’re enjoying our content, consider joining Diabetech All Access—our premium membership with exclusive stories and in-depth industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.

Diabetech content is not medical advice—and are for educational purposes only. Always consult with a physician before making changes to your healthcare.